Navigation Links
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year
Date:2/15/2013

JERSEY CITY, N.J., Feb. 15, 2013 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc.  (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2012.  Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 14, 2013.

Financial Results:

Revenues for the three and six months ended December 31, 2012 were $3,314,768 and $5,919,531, respectively, representing a 56% and a 62% increase over the revenues realized in the comparable periods of fiscal year 2012.  In both periods the increase in revenues led to a 60% increase in gross profit.  The increase in revenue was mainly attributable to the increase in sales of our main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market.  Sales of Zhongtongan accounted for 93% of sales during the quarter ended December 31, 2012. 

Aoxing Pharma completed a $10.2 million financing at the end of September 2012, which allowed it to make some crucial investments in the future of its business.  Operating expenses, therefore, were swelled during the second quarter of fiscal 2013 by two categories of targeted investment:

  • Research and development ("R&D") expenses were $1,090,104 during the three months ended December 31, 2012 and $1,219,659 during the six month period then ended, in both cases representing a several fold increase over R&D expense in fiscal 2012. 
  • Selling expenses in the amount of $1,706,202 incurred during the three months ended December 31, 2012 and $2,314
    '/>"/>

SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aoxing Pharmaceutical Company Announces Management Change
2. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For First Quarter Of 2013 Fiscal Year
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 2InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 3InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 4InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 5InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 6InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 7InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 8InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 9InteractElsevier Delivers 3-D Interactive Anatomy Learning Tools 10Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 21Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 22Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 23Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 24Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 25Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 26
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... DALLAS April 22, 2014 Researchers at UT ... people suffering from depression . , A ... major mechanism by which ghrelin (a hormone with natural ... identified a potentially powerful new treatment for depression in ... , The study, published online in April,s ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... 22 April 2014. The latest scientific advances and emerging ... Failure 2014, the main annual meeting of the Heart ... (ESC). Journalists will also hear breaking news on acute ... Heart Failure, which is part of the main congress. ... Athens, Greece, at the Megaron Athens International Conference Centre ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
... 11, 2008 The American Cancer Society announced today ... for Exemplary Leadership in Tobacco Control. The awards are ... L. Terry, M.D., who led the landmark 1964 Surgeon ... and other illnesses. Dr. Terry,s courageous and groundbreaking work ...
... Deanna Vankessel, author of the recently published G lobal Markets ... to offer extensive expertise on the recent FDA premarket approval recommendation of ... , , MRG,s Deanna Vankessel is available ... , How ...
... Begin in December - , , ... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), ... neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These ... breast cancer positive for the ErbB-2 receptor (also known as HER-2 ...
... Health Company (NYSE Alternext: FHC) has announced that the U.S. ... Committee has unanimously voted that the company,s second-generation female condom, ... , , The Advisory ... condition that the FC2 Female Condom,s instructions for use continue ...
... with ribavirin for previously untreated children with chronic hepatitis ... , KENILWORTH, N.J., Dec. 12 Schering-Plough ... the U.S. Food and Drug Administration (FDA) has granted ... USP) combination therapy for use in previously untreated patients ...
... Case Medical Center in conjunction with Sodexo Health Care Services ... 24/6 unit, the original certified kosher hot food vending machine. ... in the state of Ohio, offering patients and their caregivers ... , University Hospitals prides itself ...
Cached Medicine News:Health News:American Cancer Society recognizes international tobacco control leaders 2Health News:American Cancer Society recognizes international tobacco control leaders 3Health News:American Cancer Society recognizes international tobacco control leaders 4Health News:American Cancer Society recognizes international tobacco control leaders 5Health News:American Cancer Society recognizes international tobacco control leaders 6Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... large number of mobile, modular and transportable ... fleet. The labs are typically leased to ... The Cath Lab Leasing Company allows hospitals ... upgrading existing equipment, initiating a new service ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: